PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway
<b>Background</b>: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the recurrence and resistance of OSCC after chemo/radioresistance remains a major bottleneck for its effective...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a1855a558c4e4773ac1ec6099f77d687 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a1855a558c4e4773ac1ec6099f77d687 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a1855a558c4e4773ac1ec6099f77d6872021-11-11T16:57:17ZPDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway10.3390/ijms2221114921422-00671661-6596https://doaj.org/article/a1855a558c4e4773ac1ec6099f77d6872021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11492https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067<b>Background</b>: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the recurrence and resistance of OSCC after chemo/radioresistance remains a major bottleneck for its effective treatment. Molecular targeting is one of the new therapeutic approaches to target cancer. Among a plethora of targetable signaling molecules, PDK1 is currently rising as a potential target for cancer therapy. Its aberrant expression in many malignancies is observed associated with glycolytic re-programming and chemo/radioresistance. <b>Methods</b>: Furthermore, to better understand the role of PDK1 in OSCC, we analyzed tissue samples from 62 patients with OSCC for PDK1 expression. Combining in silico and in vitro analysis approaches, we determined the important association between PDK1/CD47/LDHA expression in OSCC. Next, we analyzed the effect of PDK1 expression and its connection with OSCC orosphere generation and maintenance, as well as the effect of the combination of the PDK1 inhibitor BX795, cisplatin and radiotherapy in targeting it. <b>Results</b>: Immunohistochemical analysis revealed that higher PDK1 expression is associated with a poor prognosis in OSCC. The immunoprecipitation assay indicated PDK1/CD47 binding. PDK1 ligation significantly impaired OSCC orosphere formation and downregulated Sox2, Oct4, and CD133 expression. The combination of BX795 and cisplatin markedly reduced in OSCC cell’s epithelial-mesenchymal transition, implying its synergistic effect. p-PDK1, CD47, Akt, PFKP, PDK3 and LDHA protein expression were significantly reduced, with the strongest inhibition in the combination group. Chemo/radiotherapy together with abrogation of PDK1 inhibits the oncogenic (Akt/CD47) and glycolytic (LDHA/PFKP/PDK3) signaling and, enhanced or sensitizes OSCC to the anticancer drug effect through inducing apoptosis and DNA damage together with metabolic reprogramming. <b>Conclusions</b>: Therefore, the results from our current study may serve as a basis for developing new therapeutic strategies against chemo/radioresistant OSCC.Shin PaiVijesh Kumar YadavKuang-Tai KuoNarpati Wesa PikatanChun-Shu LinMing-Hsien ChienWei-Hwa LeeMichael HsiaoShao-Chih ChiuChi-Tai YehJo-Ting TsaiMDPI AGarticleOSCCPDK1CD47cancer stem cellsglycolysischemo/radioresistanceBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11492, p 11492 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
OSCC PDK1 CD47 cancer stem cells glycolysis chemo/radioresistance Biology (General) QH301-705.5 Chemistry QD1-999 |
| spellingShingle |
OSCC PDK1 CD47 cancer stem cells glycolysis chemo/radioresistance Biology (General) QH301-705.5 Chemistry QD1-999 Shin Pai Vijesh Kumar Yadav Kuang-Tai Kuo Narpati Wesa Pikatan Chun-Shu Lin Ming-Hsien Chien Wei-Hwa Lee Michael Hsiao Shao-Chih Chiu Chi-Tai Yeh Jo-Ting Tsai PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| description |
<b>Background</b>: Oral squamous cell carcinoma (OSCC) has a high prevalence and predicted global mortality rate of 67.1%, necessitating better therapeutic strategies. Moreover, the recurrence and resistance of OSCC after chemo/radioresistance remains a major bottleneck for its effective treatment. Molecular targeting is one of the new therapeutic approaches to target cancer. Among a plethora of targetable signaling molecules, PDK1 is currently rising as a potential target for cancer therapy. Its aberrant expression in many malignancies is observed associated with glycolytic re-programming and chemo/radioresistance. <b>Methods</b>: Furthermore, to better understand the role of PDK1 in OSCC, we analyzed tissue samples from 62 patients with OSCC for PDK1 expression. Combining in silico and in vitro analysis approaches, we determined the important association between PDK1/CD47/LDHA expression in OSCC. Next, we analyzed the effect of PDK1 expression and its connection with OSCC orosphere generation and maintenance, as well as the effect of the combination of the PDK1 inhibitor BX795, cisplatin and radiotherapy in targeting it. <b>Results</b>: Immunohistochemical analysis revealed that higher PDK1 expression is associated with a poor prognosis in OSCC. The immunoprecipitation assay indicated PDK1/CD47 binding. PDK1 ligation significantly impaired OSCC orosphere formation and downregulated Sox2, Oct4, and CD133 expression. The combination of BX795 and cisplatin markedly reduced in OSCC cell’s epithelial-mesenchymal transition, implying its synergistic effect. p-PDK1, CD47, Akt, PFKP, PDK3 and LDHA protein expression were significantly reduced, with the strongest inhibition in the combination group. Chemo/radiotherapy together with abrogation of PDK1 inhibits the oncogenic (Akt/CD47) and glycolytic (LDHA/PFKP/PDK3) signaling and, enhanced or sensitizes OSCC to the anticancer drug effect through inducing apoptosis and DNA damage together with metabolic reprogramming. <b>Conclusions</b>: Therefore, the results from our current study may serve as a basis for developing new therapeutic strategies against chemo/radioresistant OSCC. |
| format |
article |
| author |
Shin Pai Vijesh Kumar Yadav Kuang-Tai Kuo Narpati Wesa Pikatan Chun-Shu Lin Ming-Hsien Chien Wei-Hwa Lee Michael Hsiao Shao-Chih Chiu Chi-Tai Yeh Jo-Ting Tsai |
| author_facet |
Shin Pai Vijesh Kumar Yadav Kuang-Tai Kuo Narpati Wesa Pikatan Chun-Shu Lin Ming-Hsien Chien Wei-Hwa Lee Michael Hsiao Shao-Chih Chiu Chi-Tai Yeh Jo-Ting Tsai |
| author_sort |
Shin Pai |
| title |
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| title_short |
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| title_full |
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| title_fullStr |
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| title_full_unstemmed |
PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway |
| title_sort |
pdk1 inhibitor bx795 improves cisplatin and radio-efficacy in oral squamous cell carcinoma by downregulating the pdk1/cd47/akt-mediated glycolysis signaling pathway |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/a1855a558c4e4773ac1ec6099f77d687 |
| work_keys_str_mv |
AT shinpai pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT vijeshkumaryadav pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT kuangtaikuo pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT narpatiwesapikatan pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT chunshulin pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT minghsienchien pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT weihwalee pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT michaelhsiao pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT shaochihchiu pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT chitaiyeh pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway AT jotingtsai pdk1inhibitorbx795improvescisplatinandradioefficacyinoralsquamouscellcarcinomabydownregulatingthepdk1cd47aktmediatedglycolysissignalingpathway |
| _version_ |
1718432193498316800 |